Meta-analysis of human cancers with onconet- An open-access, on-l | 25080
Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

+44 1223 790975

Meta-analysis of human cancers with onconet- An open-access, on-line knowledge base for human cancer gene mutation and expression

4th International Conference on Proteomics & Bioinformatics

August 04-06, 2014 Hilton-Chicago/Northbrook, Chicago, USA

Steven Pelech

WorkShop: J Proteomics Bioinform

Abstract :

This workshop introduces participants to the Kinexus SigNET KnowledgeBank, which is a suite of open-access knowledge bases with empirical and predictive data on protein expression and phosphorylation, protein kinases and other signalling proteins as well as protein kinase inhibitors. New websites in development include the OncoNET KnowledgeBase, which provides mutation data for 3000 human cancer-related proteins and mRNA expression data for 21,000 genes in 300 human cancer cell lines and 50 types of cancer, and KinATLAS, which graphically displays signaling pathways in a cell- and tissuespecific manner. Examples will be provided how to identify potential biomarkers and drug targets for cancer diagnosis and treatment.

Biography :

Steven Pelech has been the President and chief scientific officer of Kinexus Bioinformatics Corp. for over 14 years. He was previously the founder and president of Kinetek Pharmaceuticals, Inc. for 6 years. Prior to this, he spent 5 years in post-doctoral training with Sir Philip Cohen at the University of Dundee and Nobel laureate Dr. Edwin Krebs at the University of Washington in Seattle. He is concurrently a full professor in the Department of Medicine at the University of British Columbia (UBC), where he has been on faculty since 1988. Dr. Pelech received his BSc (1979; Honours) and PhD (1982) degrees in Biochemistry from UBC. Dr. Pelech has authored over 220 scientific peer-reviewed publications about signal transduction and is one of the discoverers of the MAP kinases. He has served on grant review panels and as an ad-hoc reviewer for over 30 granting agencies and as an external reviewer for over 30 scientific journals.